Per‐Henrik Zingmark

Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR

Hans‐Christoph Diener, Alkhedr Abdullatif, O. Busse et al. · Journal of Neurology · 2002 · 41 citations

Medicine, Neurology, Pharmacology +11

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Per‐Henrik Zingmark, Marianne Ekblom, Tomas Odergren et al. · British Journal of Clinical Pharmacology · 2003 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model

Per‐Henrik Zingmark, Matts Kågedal, Mats O. Karlsson · Journal of Pharmacokinetics and Pharmacodynamics · 2005 · 34 citations

Medicine, Biostatistics, Pharmacology +11

Comparison of proportional and differential odds models for mixed-effects analysis of categorical data

Maria C. Kjellsson, Per‐Henrik Zingmark, E. Niclas Jonsson et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2008 · 21 citations

Public Health, Biostatistics, Categorical Data Analysis +12

Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM‐027 in patients with multiple sclerosis, as measured by FACS

Per‐Henrik Zingmark, Charlotte Edenius, Mats O. Karlsson · British Journal of Clinical Pharmacology · 2004 · 18 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +17